Recent advances of diaryl ether family as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Xuwang Chen, Shufang Ding, Peng Zhan, Xinyong Liu
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Educational Ministry of China), School of Pharmaceutical Sciences, Shandong University, 44, West Culture Road, 250012 Jinan, Shandong, P.R.China.
Current pharmaceutical design 2013Diaryl ether family as one of the promising second generation HIV-1 non-nucleoside reverse transcriptase inhibitors has attracted considerable attention over the past few years, among which clinical candidate MK-4965 has been advanced into phase II clinical trials. The successful development of diaryl ether family provides valuable avenues in traditional medicinal chemistry, crystallography and computer-aided drug design fields for the design of other novel anti-HIV drug candidates. In this review, the development of diaryl ether family is present including the evolutionary history, design strategies, extensive structural modifications, structure-activity relationship studies and computer-aided molecular simulation of the binding mode in detail.
Citation
Xuwang Chen, Shufang Ding, Peng Zhan, Xinyong Liu. Recent advances of diaryl ether family as HIV-1 non-nucleoside reverse transcriptase inhibitors. Current pharmaceutical design. 2013;19(15):2829-38
Mesh Tags
Substances
PMID: 23343121
View Full Text
